The 23 companies span cancer treatments, plant genetics and robotic lung devices. Combined, they pulled in just over $6.1 billion last year.

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. | Generate:Biomedicines is the latest biotech to benefit from a ...

Generate Biomedicines has announced the pricing of its initial public offering, implying a market value of about $2 billion for the U.S. biotechnology firm. The company, which specializes in designing ...

The AI drug discovery specialist is the fifth biotechnology company to go public in February and priced the sector’s largest new stock offering in nearly three years.

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the most promising low-cost stocks to buy now. On February 10, Citi raised its price target for Roivant Sciences to $35 from $26 while maintaining a Buy ...

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best healthcare stocks under $50 to invest in. TD Cowen maintained a bullish outlook on Roivant Sciences Ltd. (NASDAQ:ROIV) on February 6, revising ...

Rashes and lesions caused by cutaneous sarcoidosis can cover much of the body, sometimes becoming disfiguring. There are no FDA-approved treatments for this rare disease, which has been overlooked by ...

Roivant Sciences is upgraded to Buy after strong Phase 2 BEACON data for brepocitinib in cutaneous sarcoidosis, highlighting blockbuster potential. Brepocitinib's once-daily oral profile and robust ...

(RTTNews) - Shares of Roivant Sciences Ltd. (ROIV) are climbing about 17 percent on Friday morning trading over the announcement of positive results from the Phase 2 study of brepocitinib in cutaneous ...

Shares of Roivant Sciences were higher after the company released positive results from a phase-two study of its brepocitinib treatment for cutaneous sarcoidosis, a skin disease. The stock rose 14% to ...

Roivant Sciences beat estimated earnings by 29.41%, reporting an EPS of $-0.24 versus an estimate of $-0.34. Revenue was down $7.02 million from the same period last year. Last quarter the company ...

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 ...